Helping you make wiser investment decisions

Pharmaceuticals, health and wellness

Shkreli hit with $64.6M verdict, lifetime pharma ban in antitrust case

About a month after Martin Shkreli’s former company inked a $40 million settlement to resolve allegations of anticompetitive conduct on toxoplasmosis drug Daraprim, the “pharma bro” has learned his fate in his own antitrust case.  A federal judge ordered the former Turing executive to pay $64.6 million in disgorgement related to money he earned from […]

Pfizer’s Cibinqo snags FDA approval to challenge Sanofi and Regeneron’s Dupixent in eczema

Look out, Sanofi and Regeneron: Pfizer is on the scene in atopic dermatitis with another blockbuster-to-be.  Friday, the FDA approved the New York drugmaker’s oral daily JAK1 inhibitor Cibinqo to treat adults with moderate to severe atopic dermatitis who have not been able to get their disease under control with other medicines including biologics and […]

Novo Nordisk comes out clean in $1.8B investor lawsuit alleging insulin misdirection

The details are slim, but Novo Nordisk seems to be in the clear after shareholders took the diabetes juggernaut to court nearly three years ago over the company’s public communications about its struggling insulin business. Novo Nordisk said Friday that it’s settled a Danish securities lawsuit from the summer of 2019. The agreement “contains no […]

JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy launches

After a false start in Europe, bluebird bio is determined to give its trio of gene therapies a better shot in the U.S.  Bluebird is readying the commercial nest ahead of a May decision on its beta thalassemia gene therapy beti-cel, also known as Zynteglo. Those preparations will be “crucial” to unlocking the blockbuster potential […]

AstraZeneca sells another half-million doses of its COVID-19 antibody combo to the US

Order up. Shortly after topping off supplies of COVID-19 drugs from Pfizer and GlaxoSmithKline, the U.S. has asked for a second helping of AstraZeneca’s antibody combo. The government has purchased an additional 500,000 doses of AZ’s long-acting antibody cocktail Evusheld, or tixagevimab plus cilgavimab. That comes on top of 700,000 doses the U.S. already ordered, […]

JPM 2022: AbbVie adjusts 2025 individual sales projections for Rinvoq and Skyrizi but not their combined total of $15B

Ahead of its state-of-the-company address at the J.P. Morgan Healthcare Conference, AbbVie took the unusual step of reconfirming its guidance for its blockbusters-in-waiting Rinvoq and Skyrizi, saying it expects the duo’s sales to reach a combined $15 billion in 2025. Why update an estimate that hasn’t changed? While AbbVie expects the two to produce the […]

JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid’s patent cliff

When Bristol Myers Squibb unveiled its massive Celgene buyout ahead of 2019’s J.P. Morgan Healthcare Conference, executives knew Celgene’s blockbuster blood cancer drug Revlimid would face generics sometime in the years that followed. In 2022, the key patent cliff is here. Fear not, BMS CEO Giovanni Caforio assured investors on Monday. Opening the conference’s 2022 […]

Catalent FDA write-up ‘allegedly’ the culprit behind Novo Nordisk’s Wegovy supply woes: report

Catalent received an FDA write-up for its syringe filling facility in Belgium, BioProcess International reports, adding that it is “allegedly” the culprit behind supply challenges for Novo Nordisk’s obesity med Wegovy. An FDA inspection of the CDMO’s filling site in Brussels yielded a Form 483, the publication said, calling it a “recent” inspection. Neither Catalent nor […]

CEO pay for Pfizer, J&J, Moderna and AstraZeneca should be tied to COVID-19 vaccine equity, investors say

COVID-19 vaccine developers have enjoyed a windfall and so have their chief executives. Now, a group of investors are asking the companies to improve vaccine equity by heaping pressure at the C-suite level. Pay packages for CEOs at COVID vaccine makers Pfizer, Johnson & Johnson, Moderna and AstraZeneca should be tied to making their shots […]

FDA must hit the gas on FOIA request tied to Pfizer’s COVID-19 vaccine, judge orders

Rather than 75 years, it will now take about eight months for the FDA to make public the information it used to license Pfizer and BioNTech’s COVID-19 vaccine—provided the regulator can keep up with the new schedule. U.S. district judge Mark Pittman on Thursday ordered the FDA to produce all remaining data on the vaccine […]

With dual approvals, Biohaven’s migraine blockbuster-in-waiting snares nearly $500M in 2021

Armed with dual approvals in migraine treatment and prevention, Biohaven Pharmaceuticals’ blockbuster-in-waiting Nurtec ODT continued to roll in 2021, ginning up nearly $500 million in revenue. Nurtec ODT, also known as rimegepant, has clinched $190 million in preliminary revenue for 2021’s fourth quarter, Biohaven said Thursday. For the entire year, the drug tallied $462 million […]

Catalent, still buzzing with pandemic momentum, taps COO Maselli to succeed Chiminski as chief executive

After two banner years on the forefront of COVID-19 vaccine production, contract manufacturing juggernaut Catalent has unveiled a changing of the guard. On July 1, Catalent’s current president and chief operating officer Alessandro Maselli will take up the mantle of chief executive officer. He’ll succeed long-time CEO John Chiminski, who’s slated to become executive chair […]